These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Sep 18, 2013
Agenus Inc. (Nasdaq: AGEN) today announced that it has received commitments from institutional investors to purchase an aggregate of approximately $6.5 million of its common stock at the market....
Sep 17, 2013Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed PatientsAnalysis of patients treated with Prophage Series G-100 (HSPPC-96) show improvement in progression free survival and overall survival versus standard of care
Agenus Inc. (Nasdaq: AGEN) today announced that a recent analysis from a Phase 2 trial in patients with newly diagnosed glioblastoma multiforme (GBM) treated with Prophage Series G-100 (HSPPC-96)...
Sep 5, 2013In Line with Independent Data Monitoring Committee’s (IDMC) Unanimous Recommendation, GSK will Continue Study Until Second Co-primary Endpoint is Assessed
Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline’s (NYSE: GSK) DERMAi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3 cancer immunotherapeuticii (CI) trial, which...
Sep 4, 2013
Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will present a corporate overview at two upcoming conferences....
Jul 25, 2013Agenus to Host Conference Call Beginning at 11 a.m. ET Today
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its...